DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection

Phase 3

Completed

Conditions: Hepatitis C Virus (HCV)

Interventions: Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
Drug: ribavirin

First Posted Date: 2015-11-20

Last Posted Date: 2019-12-10

Lead Sponsor: AbbVie

Target Recruit Count: 105

Registration Number: NCT02609659

[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis

Phase 1

Terminated

Conditions: Multiple Sclerosis

Interventions: Drug: ABT-555

First Posted Date: 2015-11-17

Last Posted Date: 2017-02-08

Lead Sponsor: AbbVie

Target Recruit Count: 4

Registration Number: NCT02606630

Locations: 🇬🇧
Site Reference ID/Investigator# 141461, Whitechapel, United Kingdom
🇬🇧
Site Reference ID/Investigator# 141463, London, United Kingdom

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection

Phase 3

Completed

Conditions: HCV
Hepatitis C Virus
Chronic Hepatitis C

Interventions: Drug: ABT-493/ABT-530

First Posted Date: 2015-11-13

Last Posted Date: 2021-07-13

Lead Sponsor: AbbVie

Target Recruit Count: 703

Registration Number: NCT02604017

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: ABT-555
Other: Placebo

First Posted Date: 2015-11-11

Last Posted Date: 2018-05-17

Lead Sponsor: AbbVie

Target Recruit Count: 20

Registration Number: NCT02601885

Locations: 🇺🇸
Rowe Neurology Institute, Lenexa, Kansas, United States
🇺🇸
Compass Research LLC, Orlando, Florida, United States
🇺🇸
Parexel International, Baltimore, Maryland, United States

and more 5 locations

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: duvelisib

First Posted Date: 2015-11-06

Last Posted Date: 2017-02-06

Lead Sponsor: AbbVie

Target Recruit Count: 7

Registration Number: NCT02598570

Locations: 🇯🇵
Site Reference ID/Investigator# 141595, Fukuoka, Japan
🇯🇵
Site Reference ID/Investigator# 141826, Aichi, Japan
🇯🇵
Site Reference ID/Investigator# 141594, Tokyo, Japan

Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: ABBV-066

First Posted Date: 2015-11-04

Last Posted Date: 2017-07-06

Lead Sponsor: AbbVie

Target Recruit Count: 80

Registration Number: NCT02596217

Locations: 🇰🇷
Boehringer Ingelheim Investigational Site, Busan, Korea, Republic of

Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma

Phase 1

Completed

Conditions: Malignant Glioma
Glioblastoma Multiforme

Interventions: Radiation: Whole Brain Radiation
Drug: Temozolomide
Drug: ABT-414

First Posted Date: 2015-10-29

Last Posted Date: 2020-09-03

Lead Sponsor: AbbVie

Target Recruit Count: 53

Registration Number: NCT02590263

Locations: 🇯🇵
University of Tsukuba Hospital /ID# 140433, Tsukuba-shi, Ibaraki, Japan
🇯🇵
Osaka University Hospital /ID# 140438, Suita-shi, Osaka, Japan
🇯🇵
Iwate Medical University Hospital /ID# 149145, Shiwa-gun, Iwate, Japan

and more 19 locations

Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2015-10-21

Last Posted Date: 2019-06-05

Lead Sponsor: AbbVie

Target Recruit Count: 173

Registration Number: NCT02582658

The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Ombitasvir/paritaprevir/ritonavir
Drug: Dasabuvir
Drug: Ribavirin

First Posted Date: 2015-10-21

Last Posted Date: 2019-05-06

Lead Sponsor: AbbVie

Target Recruit Count: 101

Registration Number: NCT02582671

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

Phase 3

Completed

Conditions: Hepatitis C Infection
Hepatitis C Virus

Interventions: Drug: ombitasvir/paritaprevir/ritonavir
Drug: dasabuvir

First Posted Date: 2015-10-21

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie

Target Recruit Count: 166

Registration Number: NCT02582632

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy